Category

Lundbeckfonden Ventures
BAGNEUX, France, Dec. 17, 2013 – DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new paradigm for the treatment of allergies, announced today a summary of corporate activities in 2013 and provided news flow guidance for 2014. Dr. Pierre-Henri Benhamou, Chairman & CEO of DBV Technologies, said: It has been an extremely...
DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new paradigm for the treatment of allergies, announced today the presentation of Epicutaneous Immunotherapy for Food Allergy” at a meeting of the World Allergy Organization by Dr. Hugh Sampson, Kurt Hisrchhorn Professor of Pediatrics, Director of the Jaffe Food Allergy Institute and Dean of...
Ongoing CUPID 2 Study Potential to Serve as Primary Basis of Efficacy and Safety Required for MMA Submission in European Union Celladon Corporation, a clinicalstage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced that the Company has received requested scientific advice from the...
. Agreement established after positive pre-clinical results were obtained by DBV and University of Geneva combining DBV’s and BioNet’s unique technologies . A Phase I, clinical proof of concept study will be initiated in H2 2014 by the University of Geneva DBV Technologies (Euronext Paris: DBV), creator of Viaskin®, announced today that it has entered...
–Continued reduction in cardiovascular events and no safety concerns observed through three years of follow up in the MYDICAR high dose group-–Oral Presentation by Dr. Barry H. Greenberg at 9 AM CET on November 19, 2013 — Celladon Corporation, a clinicalstage biotechnology company focused on developing novel therapies by applying its leadershipposition in the field...
First-in-Class Anabolic Catabolic Transforming Agent Shown to Reverse Cachexia's Effects in Stage III and IV Lung and Colorectal Cancer Patients PsiOxus Therapeutics, Ltd. (PsiOxus) today announced top line positive data from a Phase II clinical trial of MT-102 in cancer-related cachexia. The primary endpoint has been met in the recently completed Phase II multinational, randomized,...
  Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of a Phase II study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV). CINV remains a clinically significant problem in cancer patients receiving emetogenic chemotherapy despite the availability of a range of anti-emetic medications....
  BONESUPPORT AB, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced that a comprehensive review article summarizing available published and presented data for composite products containing calcium sulphate and hydroxyapatite, extensively refers to preclinical studies and clinical applications published on CERAMENTT’BONE VOID...
Study presented at the Combined Orthopaedic Research Society Meeting in Venice, Italy   BONESUPPORT AB, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced results from a five-year follow-up study on patients treated with CERAMENTT’BONE VOID FILLER, as presented at the Combined Orthopaedic Research...
  . Leading US centers in food allergy will be involved in an NIH-funded CoFAR study, coordinated by Dr. Sampson and Dr. Jones in collaboration with DBV’ team. CoFAR6 study will help to better characterize the mechanisms of action of epicutaneous immunotherapy DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new approach...
1 2 3 6